written on 24.10.2018

Cyprus Pharma Report 2018


An air of confidence is again beginning to permeate Cyprus, bolstered by the country’s key selling points: a geostrategic location close to the rest of Europe as well as the Middle East and Africa, full EU membership and norms, a favourable tax regime, a business environment conducive to growth, a large, well-educated and internationally experienced talent pool, and comparatively low costs.

Cyprus is also in the process of addressing its comparatively low levels of state expenditure on healthcare too with the implementation of a universal healthcare system – GeSY – set to be fully complete by 2020.

In this report, President of Cyprus Nicos Anastasiades gives an exclusive take on the potential impact that GeSY will have on Cyprus as a whole and numerous industry insiders – ranging from heads of local distributors and manufacturers to multinational affiliate leaders – weigh in on how GeSY will affect their operations.

Other topics discussed include Cypriot companies’ internationalization strategies, the country’s tentative steps into the medical cannabis niche, and how Cyprus is establishing itself as a premier medical tourism hotspot.

We use cookies to ensure that we give you the best experience on our site. For more info click here